Atogepant 10 mg, 30 mg, 60 mg Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 10 mg, 30 mg, 60 mg
Reference Brands: Qulipta (USA)
Category: Neurology
Atogepant is a Neurology product available as Tablets in strengths 10 mg, 30 mg, 60 mg. It corresponds to the reference brand Qulipta (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.
Product Description:
Atogepant, marketed under the brand name Qulipta, is an orally administered medication approved for the preventive treatment of episodic migraine in adults. It belongs to the class of drugs known as gepants, which are calcitonin gene-related peptide (CGRP) receptor antagonists. By selectively blocking CGRP receptors, atogepant helps reduce the frequency, severity, and impact of migraine attacks, providing an effective prophylactic option for patients who experience recurrent migraines.
As a once-daily oral therapy, atogepant offers a convenient alternative to injectable migraine-preventive treatments. Clinical studies have shown that it significantly lowers the number of migraine days per month, improving overall quality of life for adults living with episodic migraine. The medication is generally well-tolerated, with the most common side effects including nausea and constipation. Atogepant represents a modern, targeted approach to migraine prevention, providing patients and healthcare providers with a valuable tool for long-term management of this debilitating neurological condition.
Atogepant — third party manufacturing & bulk supply
Atogepant 10 mg, 30 mg, 60 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Atogepant listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Atogepant →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Atogepant is used for the preventive treatment of episodic migraine in adults, reducing the number of migraine days and improving patient quality of life.
Atogepant is a synthetic small-molecule CGRP receptor antagonist designed to block the activity of calcitonin gene-related peptide, a key mediator in migraine pathophysiology.
The trade name of atogepant is Qulipta.
Qulipta is developed and marketed by AbbVie Inc. in the United States.
The complete generic name is atogepant.
The brand name is Qulipta.
Atogepant tablets are manufactured in FDA-approved pharmaceutical facilities for the U.S. market, with production details disclosed by AbbVie in regulatory filings.
Related Products
Valproic Acid
Strength:
125 mg/mL, 200 mg, 250 mg, 300 mg, 500 mg, 100 mg/mL
Form: Tablet / Capsule/ Injection / Oral syrup
Reference Brands: Depakene (USA), Depakine (EU/LATAM), Valprol (India)
View Details
Quick Response Guaranteed | Verified Suppliers
